U.S. Court of Appeals for the Federal Circuit, 2024

Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc.

Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc.
U.S. Court of Appeals for the Federal Circuit · Decided August 20, 2024

Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc.

Opinion

Case: 24-1564 Document: 28 Page: 1 Filed: 08/20/2024

NOTE: This order is nonprecedential.

United States Court of Appeals for the Federal Circuit ______________________ REGENERON PHARMACEUTICALS, INC., Appellant v. MYLAN PHARMACEUTICALS INC., CELLTRION, INC., SAMSUNG BIOEPIS CO., LTD., Appellees ______________________ 2024-1564, 2024-1567 ______________________ Appeals from the United States Patent and Trademark Office, Patent Trial and Appeal Board in Nos. IPR2022- 01225, IPR2022-01226, IPR2023-00532, IPR2023-00533, and IPR2023-00566. ______________________ ON MOTION ______________________ ORDER Upon consideration of Regeneron Pharmaceuticals, Inc.’s unopposed motion to voluntarily dismiss the above- captioned appeals pursuant to Federal Rule of Appellate Procedure 42, Case: 24-1564 Document: 28 Page: 2 Filed: 08/20/2024

2 REGENERON PHARMACEUTICALS, INC. v. MYLAN PHARMACEUTICALS INC.

IT IS ORDERED THAT: (1) The motion is granted, and the appeals are dis- missed. (2) Each party shall bear its own costs for each appeal.

FOR THE COURT

August 20, 2024 Date ISSUED AS A MANDATE: August 20, 2024

Case-law data current through December 31, 2025. Source: CourtListener bulk data.